1080. Relebactam Increases Imipenem Activity Against Imipenem-Nonsusceptible and -Susceptible Pseudomonas aeruginosa and Enterobacterales: Assessment of Isolates from RESTORE-IMI 2

BACKGROUND: Relebactam (REL) inhibits class A and C β-lactamases (BLs) and is approved in the US in the combination imipenem/cilastatin/REL (IMI/REL) for hospital acquired bacterial pneumonia (HABP) and ventilator associated bacterial pneumonia (VABP), and also in patients with limited treatment opt...

Descripción completa

Detalles Bibliográficos
Autores principales: Hilbert, David W, Andrew DeRyke, C, Losada, Maria C, Moise, Pamela, Chen, Luke F, Young, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644246/
http://dx.doi.org/10.1093/ofid/ofab466.1274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644246/
http://dx.doi.org/10.1093/ofid/ofab466.1274

Ejemplares similares